Sarcomatoid
Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
Cancers 2020 December 20 [Link] Roberta Affatato, Paolo Mendogni, Alessandro Del Gobbo, Stefano Ferrero, Francesca Ricci, Massimo Broggini, Lorenzo Rosso Abstract Background: Malignant pleural mesothelioma (MPM) is a very aggressive tumor originating from mesothelial cells. Although several etiological factors were reported to contribute to MPM onset, environmental exposure to asbestos is certainly a major risk…
Read MoreClinical features and surgical outcomes of major urological interventions during cytoreductive surgery and hyperthermic intraperitoneal chemotheraphy
Therapeutic Advances in Urology 2020 December 10 [Link] Özgül Düzgün, Murat Kalın, Resul Sobay, Ömer Faruk Özkan Abstract Background: Urinary system resections and reconstructions are needed in peritoneal carcinomatosis due to abdominal malignancies. The effect of hyperthermic intraperitoneal chemotherapy on these urological procedures after reconstruction remains uncertain. The aim of the study is to evaluate…
Read MoreThe potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas
Human Pathology 2020 September 2 [Link] Sarita Prabhakaran, Ashleigh Hocking, Chankyung Kim, Matthew Hussey, Sonja Klebe Abstract Malignant pleural mesothelioma is associated with asbestos exposure and poor outcomes. The usefulness of immunohistochemistry for diagnosis of sarcomatoid mesothelioma, especially the desmoplastic type, is limited, and more effective markers are required. GATA binding protein 3 (GATA3) has…
Read MoreTrabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study
Clinical Lung Cancer 2020 July 3 [Link] Diego Cortinovis, Federica Grosso, Luciano Carlucci, Paolo Andrea Zucali, Giulia Pasello, Marcello Tiseo, Francesca Sperandi, Lital Hollander, Francesca Galli, Valter Torri, Eliana Rulli, Stefania Canova, Antonio Maconi, Paolo Bidoli, Giovanni Luca Ceresoli , Maurizio D’Incalci, ATREUS investigators Abstract Introduction: New therapeutic approaches in unresectable malignant pleural mesothelioma (MPM)…
Read MoreDeterminants of plasma calretinin in patients with malignant pleural mesothelioma
BMC Research Notes 2020 July 29 [Link] Martin Lehnert, Daniel G Weber, Dirk Taeger, Irina Raiko, Jens Kollmeier, Susann Stephan-Falkenau, Thomas Brüning, Georg Johnen, MoMar-Study Group Abstract Objective: Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey,…
Read MorePossible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
Respiratory Research 2020 July 16 [Link] Masataka Kojima, Kazunori Kajino, Shuji Momose, Nadila Wali, May Thinzar Hlaing, Bo Han, Liang Yue, Masaaki Abe, Tomoaki Fujii, Katsuhisa Ikeda, Okio Hino Abstract Background: Mesothelioma is histologically divided into three subgroups: epithelioid, sarcomatoid, and biphasic types. The epithelioid or sarcomatoid type is morphologically defined by polygonal or spindle-like…
Read MoreAmrubicin in Previously Treated Patients With Malignant Pleural Mesothelioma: A Phase II Study
Thoracic Cancer 2020 May 28 [Link] Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae Abstract Background: The aim of this study was to assess the efficacy and safety of amrubicin for previously treated…
Read MoreUse of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions
Archives of Pathology and Laboratory Medicine 2020 February [Link] Fatemeh Derakhshan, Diana Ionescu, Simon Cheung, Andrew Churg Abstract Context.—: The separation of benign from malignant mesothelial proliferations is a difficult morphologic problem. Some mesotheliomas stain for programmed death ligand-1 (PD-L1). Objective.—: To determine whether PD-L1 staining can separate mesotheliomas from reactive mesothelial proliferations (RMPs). Design.—:…
Read MoreA case report of malignant primary pericardial mesothelioma with atypical imaging appearance: multimodality imaging with histopathological correlation.
European Heart Journal 2020 February 27 [Link] Banišauskaitė A, Jankauskas A, Šarauskas V, Aržanauskaitė M Abstract BACKGROUND :Primary pericardial mesothelioma is a rare primary cardiac malignancy, with three main histopathological types, sarcomatoid histotype being the rarest. The imaging features were atypical due to concomitant extensive calcification, which resulted in aggravated differential diagnosis. CASE SUMMARY :A 45-year-old man…
Read MoreOverexpression of miR-199/214 is a distinctive feature of iron- and asbestos-induced sarcomatoid mesothelioma in rats.
Cancer Science 2020 April 4 [Link] Okazaki Y, Chew SH, Nagai H, Yamashita Y, Ohara H, Li J, Akatsuka S, Takahashi T, Toyokuni S Abstract Malignant mesothelioma (MM) is one of the most lethal tumors in humans. The onset of MM is linked to exposure to asbestos, which generates reactive oxygen species (ROS). ROS are…
Read More